Release Date: February 1, 2007
Valid Through: January 31, 2008
Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)TM
Fee: There is no fee for this activity
This CME activity is based on the following interactive case study:
Case Study in Refractory Anemia with Excess Blasts in Transformation
Ravi Vij, MD, Washington University in St. Louis School of Medicine
Learning Objectives
Upon completion of this activity, participants should be able to:
- Understand survival data and quality of life issues when azacitidine is used for the treatment of MDS.
- Discuss data regarding lenalidomide in high-risk patients with MDS.
- Evaluate data regarding azacitidine among high-risk patients with MDS.
- Discuss outcomes among patients with MDS who were treated with standard versus reduced-intensity allogeneic stem cell transplants among patients with MDS.
Disclaimer
Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .
Supporters
This activity is supported by an unrestricted educational grant from Pharmion.
